Pielotax

Also known as: A-9 Kidney Peptide Bioregulator

Overview

Pielotax is a renal-specific peptide complex that restores kidney function by targeting renal tubular and mesangial cells. It modulates gene expression to repair tissue, reduce inflammation, and improve glomerular filtration.

Benefits

- Improves nephron filtration

- Reduces renal inflammation

- Reverses fibrosis

- Supports erythropoietin output

- Aids recovery from nephrotoxicity

Consider This Peptide If You Want To

- Support kidney repair and reduce inflammation

- Aid renal recovery post-medication or illness

Dosage & Administration

Dosage Guidelines

Recommended Dosage

• Amount:30 mg

• Frequency:daily

• Duration:4 weeks

• Rest Period:12 weeks

• Time of Day:morning

• Ingestion:oral

Take with food to optimize absorption. Monitor kidney function during treatment.

Administration Routes:Oral

Research Findings on Dosage:

Oral Administration

• Commonly Reported Dosage: 1-2 capsules (0.215 g each) twice daily (this equates to 20-40 mg of peptide complex A-9)

• Duration: 30 days, repeat every 4--6 months chronically, or more frequently in acute support phases

Administration Notes: Take with food to optimize absorption and renal metabolism

Mechanism of Action

Mechanism of Action

How this peptide works in the body

Chromatin Remodeling in Renal Tissue

Pielotax increases euchromatin availability in renal tubular epithelial cells by upregulating histone acetylation marks (e.g., H3K9ac, H3K27ac), while decreasing repressive marks like H3K27me3. This promotes transcription of genes such as SLC12A3 (a sodium-chloride transporter), AQP2 (aquaporin-2), and EPO (erythropoietin).

Renal Anti-Inflammatory Signaling

It suppresses activation of NF-κB in mesangial and tubular cells, decreasing expression of MCP-1, IL-6, and TNF-α. Pielotax also reduces leukocyte adhesion molecule expression (ICAM-1, VCAM-1), protecting glomeruli from immune infiltration and fibrosis.

Fibrosis Regulation and ECM Remodeling

Pielotax inhibits TGF-β1-induced fibrotic signaling by downregulating SMAD2/3 phosphorylation. It upregulates MMP-2 and MMP-9 and decreases TIMP expression, supporting extracellular matrix (ECM) clearance and reducing renal interstitial fibrosis.

Electrolyte Transport and Nephron Function

Through upregulation of SLC transporter genes and Na+/K+ ATPase expression, Pielotax enhances reabsorption efficiency in distal and collecting tubules. It improves urine concentrating ability and restores solute balance in chronic kidney impairment.

Hormonal Modulation and Erythropoiesis

Pielotax promotes expression of erythropoietin in peritubular fibroblasts by relieving epigenetic repression of the EPO gene. It may indirectly normalize renin-angiotensin signaling by restoring baroreceptor feedback sensitivity in juxtaglomerular cells.

Consider Stacking With

- Ventfort

- Thymalin

- Endoluten

- Livagen

- Glandokort

Side Effects & Cautions

Common Side Effects

- None documented

Cautions

- Use under supervision for renal disease

- Monitor when on diuretics/antihypertensives

Rare Side Effects

- Rare allergic reactions

Research & References

Research Highlights

Khavinson et al., 2022: Reported nephroprotective gene upregulation and inflammation reduction in renal cell cultures treated with Pielotax.

Trofimova et al., 2013: Demonstrated improved creatinine clearance and reduced proteinuria in early-stage CKD patients after peptide use.

Umnov et al., 2011: Observed ECM remodeling and reduced mesangial matrix expansion in biopsy-confirmed nephropathy cases.

Khavinson & Morozov, 2009: Identified epigenetic gene activation pathways specific to renal peptide bioregulators.

References

Khavinson V, et al. "Peptide regulation of renal gene networks in nephropathy models." Int J Mol Sci. 2022.

Trofimova SV, et al. "Efficacy of peptide complexes in early chronic kidney disease." Russian J Gerontology. 2013.

Umnov RS, et al. "Histological evaluation of renal bioregeneration using short peptides." Peptide Therapy Reports. 2011.

Khavinson V, Morozov VG. "Tissue-specific peptides in renal repair and aging." 2009.